BioSpace News Archive

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that it has commenced an underwritten public offering of $150.0 million of its common stock.

Thryv Therapeutics Inc. is excited to announce the evolution of its portfolio to include treatments for resistant and rare cancers.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 34,500 shares of the Company’s common stock at an exercise price per share of $28.78, which was the closing price on July 8, 2022, and restricted stock units to acquire a total of 17,250 shares of the Company’s common stock.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company’s Chief Financial Officer, effective immediately.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the closing of its private placement, resulting in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that the US Food & Drug Administration (“FDA”) has granted Breakthrough Device designation for the Company’s Toraymyxin™ (“PMX”) device, a therapeutic hemoperfusion device that removes endotoxin, which can cause septic shock.

Lipocine Inc announced today that the U.S. Food and Drug Administration (“FDA”) has accepted the company’s Investigational New Drug Application (“IND”) for its neuroactive steroid (“NAS”) candidate, LPCN 2101, as a potential treatment for adults with epilepsy.

To commemorate Graves’ Disease Awareness Month this July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with all-star patient advocates, Wanda Durant and Gail Devers, to help others living with Graves’ disease know their risk for a separate, but related, condition called Thyroid Eye Disease.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company has been invited to present at the Women’s Health Panel Discussion, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, July 13th, 2022 at 11:00 a.m. ET.